Product Description
Bexarotene is used to treat cutaneous T-cell lymphoma (CTCL, a type of skin cancer) in people whose disease could not be treated successfully with at least one other medication. Bexarotene is in a class of medications called retinoids. It works by stopping the growth of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a608006.html)
Mechanisms of Action: RXR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Belgium | Brazil | Chile | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Peru | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Turkey | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: T-Cell Leukemia|T-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-194908 | P2 |
Active |
T-Cell Leukemia|T-Cell Lymphoma |
2023-12-31 |